KRAS and colorectal cancer: Profiling of KRAS-expressing intestinal epithelioid cells IEC-6 with the combination of state-of-the-art cell surface proteomics and CRISPR/Cas-9 screens identified ATP7A as a lethal synthetic partner in KRAS-mutant colorectal cancers [116].